Literature DB >> 10929035

Expression of urokinase plasminogen activator and the urokinase plasminogen activator receptor in myeloma cells.

O Hjertner1, G Qvigstad, H Hjorth-Hansen, C Seidel, J Woodliff, J Epstein, A Waage, A Sundan, M Börset.   

Abstract

Binding of urokinase (uPA) to its receptor (uPAR; CD87) focuses proteolytic activity on the cell surface and this system is of importance in malignant matrix degradation and tumour invasion. By immunocytochemistry and flow cytometry, we found that primary myeloma cells and myeloma cell lines expressed uPA and uPAR. Soluble uPA was present in cell line supernatants and lysates in low concentrations. In cell lines, uPA and uPAR were located both on the cell surface and intracellularly, but the expression of both proteins was low. Higher levels of uPAR was detected on the cell surface of primary myeloma cells. When primary myeloma cells were gated by CD45 expression, stronger expression was found on immature CD45+ cells than on mature CD45-/dim cells. Finally, both myeloma cell lines and primary cells were able to cleave a uPA-specific substrate showing that the uPA system is functionally active. We conclude that myeloma cells are able to produce uPA and uPAR. This opens up a possible role of the uPA system in myeloma cell invasion and in the proteolytic digestion of bone matrix.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10929035     DOI: 10.1046/j.1365-2141.2000.02089.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  11 in total

1.  Analysis of soluble urokinase plasminogen activator receptor in multiple myeloma for predicting prognosis.

Authors:  Jie Shen; Qing Wang; Juan Wang; Guo-Hong Su; Juan Wang; Sheng-Hu Guo; Y A Liu; Zheng Wu; Rong-Feng Liu; Xing Li; Xiao-Jin Guo; Jing Cao; Yue-Hua Zhang; Zhi-Yu Wang
Journal:  Oncol Lett       Date:  2015-08-14       Impact factor: 2.967

2.  Development of novel therapeutics targeting the urokinase plasminogen activator receptor (uPAR) and their translation toward the clinic.

Authors:  Andrew P Mazar; Richard W Ahn; Thomas V O'Halloran
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

Review 3.  Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis.

Authors:  Arun Balakumaran; Pamela Gehron Robey; Neal Fedarko; Ola Landgren
Journal:  Expert Rev Mol Diagn       Date:  2010-05       Impact factor: 5.225

4.  Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma.

Authors:  Anurag Purushothaman; Ligong Chen; Yang Yang; Ralph D Sanderson
Journal:  J Biol Chem       Date:  2008-09-23       Impact factor: 5.157

5.  Augmented expression of urokinase plasminogen activator and extracellular matrix proteins associates with multiple myeloma progression.

Authors:  Rehan Khan; Nidhi Gupta; Raman Kumar; Manoj Sharma; Lalit Kumar; Alpana Sharma
Journal:  Clin Exp Metastasis       Date:  2014-05-08       Impact factor: 5.150

6.  Mechanisms involved in the differential bone marrow homing of CD45 subsets in 5T murine models of myeloma.

Authors:  Kewal Asosingh; Eline Menu; Els Van Valckenborgh; Isabelle Vande Broek; Ivan Van Riet; Ben Van Camp; Karin Vanderkerken
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

7.  Murine 5T multiple myeloma cells induce angiogenesis in vitro and in vivo.

Authors:  E Van Valckenborgh; H De Raeve; L Devy; S Blacher; C Munaut; A Noël; E Van Marck; I Van Riet; B Van Camp; K Vanderkerken
Journal:  Br J Cancer       Date:  2002-03-04       Impact factor: 7.640

8.  u-PAR expression in cancer associated fibroblast: new acquisitions in multiple myeloma progression.

Authors:  S Ciavarella; A Laurenzana; S De Summa; B Pilato; A Chillà; R Lacalamita; C Minoia; F Margheri; A Iacobazzi; A Rana; F Merchionne; G Fibbi; M Del Rosso; A Guarini; S Tommasi; S Serratì
Journal:  BMC Cancer       Date:  2017-03-24       Impact factor: 4.430

Review 9.  The many spaces of uPAR: delivery of theranostic agents and nanobins to multiple tumor compartments through a single target.

Authors:  Thomas V O'Halloran; Richard Ahn; Patrick Hankins; Elden Swindell; Andrew P Mazar
Journal:  Theranostics       Date:  2013-06-25       Impact factor: 11.556

10.  Urokinase-type plasminogen activator receptor as a predictor of poor outcome in patients with systemic inflammatory response syndrome.

Authors:  Xiao-Ling Wu; Ding Long; Li Yu; Jun-Hui Yang; Yuan-Chao Zhang; Feng Geng
Journal:  World J Emerg Med       Date:  2013
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.